Two other studies have reported the relief of doxorubicin resistance by HSP70 inhibitors in breast cancer, through the Mint3-HIF-1-HSP70 pathway and the DNAJC12-HSP70-AKT pathway [24,25]. This evidence concerns the gene DNAJC12 and breast carcinoma.